Mirati Therapeutics

Health biotech drug development oncology pharma

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

Market capitalization(2017-09-22)

$245.8 M

Type

Public

San Diego, US

Founded

2013

Size (employees)

38 (est)

Website

mirati.com

Mirati Therapeutics was founded in 2013 and is headquartered in San Diego, US

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego

San Diego, US (HQ)

200 9393 Towne Centre Dr

Mirati Therapeutics Data and Metrics

Mirati Therapeutics Financial Metrics

Summary

USD

Mirati Therapeutics's current market capitalization is $245.8 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
R&D expense				68.5 m
General and administrative expense				15.3 m
Operating expense total				83.8 m
EBIT	(32 m)	(39.1 m)	(64.7 m)	(83.8 m)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
R&D expense	7.2 m	7 m	8.2 m	11.3 m	14.6 m	18 m	18.4 m	16.1 m	14.4 m
General and administrative expense	2.9 m	3.5 m	3.8 m	4.2 m	4.2 m	4.1 m	3.8 m	3.5 m	3.7 m
Operating expense total	10.1 m	10.5 m	12 m	15.5 m	18.7 m	22.1 m	22.2 m	19.6 m	18.1 m
EBIT	(10.1 m)	(10.5 m)	(12 m)	(15.5 m)	(18.7 m)	(22.1 m)	(22.2 m)	(19.6 m)	(18.1 m)

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	14.2 m	6.6 m	49.5 m	22.4 m
Current Assets	64.2 m	32.7 m	125.4 m	59.6 m
PP&E	322 k	496 k	614 k	629 k
Total Assets	64.5 m	33.5 m	128 m	63.4 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	8.5 m	4.9 m	14.3 m	13.4 m	109.9 m	34.6 m	24.5 m	19.8 m	29.8 m
Current Assets	49.2 m	40.3 m	71.2 m	60.9 m	141 m	109.9 m	93 m	75.5 m	107.9 m
PP&E	479 k	524 k	667 k	693 k	639 k	601 k	558 k	537 k	638 k
Total Assets	49.7 m	41.3 m	72.2 m	61.9 m	143.7 m	112.5 m	96 m	79.2 m	110.8 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income		(43.7 m)	(64.5 m)	(83.1 m)
Depreciation and Amortization	171 k	199 k	212 k	180 k
Cash From Operating Activities			(50.7 m)	(68 m)
Purchases of PP&E	(204 k)	(386 k)	(329 k)	(196 k)